Persistent Angina After Second-Line Anti-Anginal Therapy in Ischemic Heart Disease
This protocol applies to patients with ischemic heart disease whose angina remains inadequately controlled after a second anti-anginal agent has been added to beta-blocker therapy — and escalation to a further treatment step is required.
Prior Line — Failure Condition
The previous step added a calcium channel blocker, or a long-acting nitrate (isosorbide mononitrate or isosorbide dinitrate), as second-line anti-anginal therapy following beta-blockers. The intended goals — reduction in angina symptoms and episodes, and improved exercise capacity — were not sufficiently achieved, triggering escalation to this protocol.
Next-Step Treatment — Partial Overview
When symptoms persist despite the prior agents, or when their use is limited by tolerability, a further class of anti-anginal agent is considered — including agents such as ranolazine, which carries a Class IIa recommendation from European and American guidelines in this setting.
Full treatment options, alternatives, and dosing details are in the structured protocol below.
Treatment Goals
- Reduction in the frequency of angina attacks
- Decreased need for sublingual nitrates
- Increased angina-free exercise time
References
DOI: 10.1093/eurheartj/suaa060
- The guidelines suggest it if the symptoms are not well-controlled with BB, calcium channel blockers, or nitrates or if hypotension and bradycardia limit the use of these drugs (Class IIa indication of European and American guidelines).
- The study, carried out with 12-week follow-up, involved 823 adults with chronic symptomatic angina, who were randomized to receive placebo or two different dosages of ranolazine (750 mg or 1000 mg 2/day).
- Several studies have confirmed the effectiveness of ranolazine in reducing angina symptoms and angina-free exercise time.
- In the treated group a reduction in the frequency of angina attacks and a reduction in the use of sublingual nitrates was highlighted.
View source ↗